These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37608073)

  • 21. Rearrangements of the fibrin network and spatial distribution of fibrinolytic components during plasma clot lysis. Study with confocal microscopy.
    Sakharov DV; Nagelkerke JF; Rijken DC
    J Biol Chem; 1996 Jan; 271(4):2133-8. PubMed ID: 8567670
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of flow on lysis of plasma clots in a plasma environment.
    Sakharov DV; Rijken DC
    Thromb Haemost; 2000 Mar; 83(3):469-74. PubMed ID: 10744155
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Computer simulation of systemic circulation and clot lysis dynamics during thrombolytic therapy that accounts for inner clot transport and reaction.
    Anand S; Diamond SL
    Circulation; 1996 Aug; 94(4):763-74. PubMed ID: 8772700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-time measurement of lysis of mural platelet deposits by fibrinolytic agents under arterial flow.
    Graham DA; Huang TC; Keyt BA; Alevriadou BR
    Ann Biomed Eng; 1998; 26(4):712-24. PubMed ID: 9662163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel simultaneous clot-fibrinolysis waveform analysis for assessing fibrin formation and clot lysis in haemorrhagic disorders.
    Nogami K; Matsumoto T; Sasai K; Ogiwara K; Arai N; Shima M
    Br J Haematol; 2019 Nov; 187(4):518-529. PubMed ID: 31335970
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fibrinolytic PLGA nanoparticles for slow clot lysis within abdominal aortic aneurysms attenuate proteolytic loss of vascular elastic matrix.
    Sivaraman B; Sylvester A; Ramamurthi A
    Mater Sci Eng C Mater Biol Appl; 2016 Feb; 59():145-156. PubMed ID: 26652359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Model thrombi formed under flow reveal the role of factor XIII-mediated cross-linking in resistance to fibrinolysis.
    Mutch NJ; Koikkalainen JS; Fraser SR; Duthie KM; Griffin M; Mitchell J; Watson HG; Booth NA
    J Thromb Haemost; 2010 Sep; 8(9):2017-24. PubMed ID: 20586921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fibrinolysis in Venous Thromboembolism.
    Undas A
    Semin Thromb Hemost; 2021 Jul; 47(5):480-489. PubMed ID: 33878786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endogenous fibrinolysis-Relevance to clinical thrombosis risk assessment.
    Kanji R; Kubica J; Navarese EP; Gorog DA
    Eur J Clin Invest; 2021 Apr; 51(4):e13471. PubMed ID: 33296082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fibrin Clot Formation and Lysis in Plasma.
    Larsen JB; Hvas AM
    Methods Protoc; 2020 Sep; 3(4):. PubMed ID: 32993011
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biochemical and biophysical conditions for blood clot lysis.
    Šabovič M; Blinc A
    Pflugers Arch; 2000 Jan; 440(Suppl 1):R134-R136. PubMed ID: 28008511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species.
    Gurewich V; Pannell R; Louie S; Kelley P; Suddith RL; Greenlee R
    J Clin Invest; 1984 Jun; 73(6):1731-9. PubMed ID: 6725557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fibrinolysis and the control of blood coagulation.
    Chapin JC; Hajjar KA
    Blood Rev; 2015 Jan; 29(1):17-24. PubMed ID: 25294122
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stretching single fibrin fibers hampers their lysis.
    Li W; Lucioni T; Li R; Bonin K; Cho SS; Guthold M
    Acta Biomater; 2017 Sep; 60():264-274. PubMed ID: 28754649
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determinants of plasma fibrin clot lysis measured using three different assays in healthy subjects.
    Siudut J; Iwaniec T; Plens K; Pieters M; Undas A
    Thromb Res; 2021 Jan; 197():1-7. PubMed ID: 33157491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity.
    Günther A; Markart P; Kalinowski M; Ruppert C; Grimminger F; Seeger W
    Am J Respir Cell Mol Biol; 1999 Dec; 21(6):738-45. PubMed ID: 10572071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The spatial dynamics of fibrin clot dissolution catalyzed by erythrocyte-bound vs. free fibrinolytics.
    Gersh KC; Zaitsev S; Muzykantov V; Cines DB; Weisel JW
    J Thromb Haemost; 2010 May; 8(5):1066-74. PubMed ID: 20149071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor.
    Ammollo CT; Semeraro F; Incampo F; Semeraro N; Colucci M
    J Thromb Haemost; 2010 Apr; 8(4):790-8. PubMed ID: 20088944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fibrinolysis in trauma patients: wide variability demonstrated by the Lysis Timer.
    Roullet S; Weinmann L; Labrouche S; Gisbert-Mora C; Biais M; Revel P; Freyburger G
    Scand J Clin Lab Invest; 2019; 79(1-2):136-142. PubMed ID: 30861350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.